SMC accepts dapagliflozin (ForxigaT) for restricted use in adults patients with type 2 diabetes mellitus

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium has accepted dapagliflozin (ForxigaT) for restricted use within NHS Scotland in adults patients with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.   The SMC states that dapagliflozin is restricted to use as dual therapy in combination with metformin, when metformin alone with diet and exercise does not provide adequate glycaemic control and a sulphonylurea is inappropriate.   The drug advice (see link below) summarises the safety and efficacy data considered for this drug in this indication. This notes that in three phase III randomised, controlled studies, dapagliflozin when added to metformin was non-inferior to a sulphonylurea in combination with metformin, and superior to placebo in terms of glycaemic control, as measured by change in HbA1c. This was ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news